首页> 外文期刊>Radiation oncology >Analyses of distribution and dosimetry of brain metastases in small cell lung cancer with relation to the neural stem cell regions: feasibility of sparing the hippocampus in prophylactic cranial irradiation
【24h】

Analyses of distribution and dosimetry of brain metastases in small cell lung cancer with relation to the neural stem cell regions: feasibility of sparing the hippocampus in prophylactic cranial irradiation

机译:与神经干细胞区域有关的小细胞肺癌中脑转移的分布和剂量学分析:在预防性颅脑照射中保留海马体的可行性

获取原文
获取外文期刊封面目录资料

摘要

Background This work aims to assess the feasibility of selectively sparing the hippocampus during prophylactic cranial irradiation (PCI) for small cell lung cancer (SCLC). Methods SCLC patients with brain metastases (BMs) diagnosed with MRI were enrolled. Lesions localized to the neural stem cell (NSC) compartments [subventricular zone (SVZ) or hippocampus] were analyzed. Patients were categorized by the total number of intracranial metastases, the therapy processes and the symptoms. Hippocampi and enhanced lesions within 15?mm from the hippocampus were contoured. IMRT treatment plans were generated for hippocampal avoidance (HA)-PCI (25Gy in 10 fractions). Results From Jan 2011 to Oct 2014, 1511 metastases were identified in 238 patients. The overall ratio of metastatic lesions located in NSC regions was 2.0% in the 1511 total metastases and 9.7% in the 238 overall patients. Among the NSC region metastases, 15 (1.0%) lesions involved the HA region of 14 (5.9%) patients and another 15 (1.0%) involved the SVZ of 15 (6.3%) patients. The involvement of HA region or SVZ was significantly different between patients with oligometastatic and non-oligometastatic BMs ( P Conclusions Our retrospective review of 1511 metastases in 238 patients (among whom 89.5% were male) suggests that the metastatic involvement of the NSC regions (especially hippocampus) is unusual and limited primarily to patients with non-oligometastatic disease in SCLC. Also, dosimetric analysis shows that about 10% of patients may have adequate dosage due to HA-PCI treatment. But we believe that this is still an acceptable clinical treatment strategy for SCLC.
机译:背景技术这项工作旨在评估在预防性颅脑照射(PCI)期间针对小细胞肺癌(SCLC)选择性保留海马的可行性。方法招募经MRI诊断为SCLC的脑转移瘤(BMs)患者。分析了位于神经干细胞(NSC)区室[脑室下区域(SVZ)或海马]的病变。根据颅内转移的总数,治疗过程和症状对患者进行分类。对海马和距海马15毫米内的病灶增强进行轮廓绘制。针对海马回避(HA)-PCI(25Gy分10个部分)制定了IMRT治疗计划。结果2011年1月至2014年10月,在238例患者中发现了1511处转移。位于NSC区域的转移性病变的总比例在1511例总转移中为2.0%,在238例整体患者中为9.7%。在NSC区转移中,有15(1.0%)个病变累及14个(5.9%)患者的HA区,另外15个(1.0%)累及15个(6.3%)患者的SVZ。少转移性和非转移性BM患者的HA区域或SVZ的受累程度显着不同(P结论我们对238例患者中1511例转移的回顾性回顾(其中89.5%为男性)表明,NSC区域的转移受累(尤其是海马)并不常见,并且主要限于SCLC中的非低转移性疾病患者;剂量分析表明,大约有10%的患者因HA-PCI治疗而有足够的剂量,但我们认为这仍然是可接受的临床治疗方法SCLC的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号